Main Article Content
Sepsis is an inflammation syndrome which is caused by severe infection. This severe inflammation is characterized by vasodilatation, leukocyte accumulation and increased microvascular permeability. The pathophysiology of sepsis is believed to be due to the dysregulation of the inflammatory response. The human body generates and releases a massive uncontrolled amount of proinflammatory mediators into the blood stream which causes cellular and tissue injury. This injury leads to the development of multiple organ dysfunction syndromes (MODS), and causes life-threatening conditions.
This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
2. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock:2008. Crit Care Med 2008; 36:296-327.
3. Hollenberg SM, Ahrens TS, Annane D, et al. Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. Crit Care Med 2004;32:1928-48.
4. Practice parameters for hemodynamic support of sepsis in adult patients in sepsis. Task Force of the American College of Critical Care Medicine. Crit Care Med 1999; 27:639-60.
5. Bernard GR, Wheeler AP, Russell JA, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med 1997;336:912-8.
6. McCloskey RV, Straube RC, Sanders C, et al. Treatment of septic shock with human monoclonal antibody HA-1A.A randomized, double-blind,placebo-controlled trial.CHESS Trial Study Group. Ann Intern Med 1994;121:1-5.
7. Zeni F, Freeman B, Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock; a reassessment. Crit Care Med 1997;25:1095-100.
8. Sasse KC, Nauenberg E, Long A, et al. Long-term survival after intensive care unit admission with sepsis. Crit Care Med 1995;23:1040-7.
9. Nakada TA, Oda S, Matsuda K, et al. Continuous hemodiafiltration with PMMA Hemofilter in the treatment of patients with septic shock. Mol Med 2008;14:257-63.
10. Tetta C, Cavaillon JM, Camussi G, et al. Continuous plasma filtration coupled with sorbents. Kidney Int Suppl 1998;66:186-9.
11. Tetta C, Gianotti L, Cavaillon JM, et al. Coupled plasma filtration-adsorption in a rabbit model of endotoxic shock. Crit Care Med 2000;28:1526-33.
12. Ronco C, Brendolan A, Lonnemann G, et al. A pilot study of coupled plasma filtration with adsorption in septic shock. Crit Care Med 2002;30:1250-5.
13. Bellomo R, Tetta C, Ronco C. Coupled plasma filtration adsorption. Intensive Care Med 2003;29:1222-8.
14. Formica M, Olivieri C, Livigni S, et al. Hemodynamic response to coupled plasmafiltration-adsorption in human septic shock. Intensive Care Med 2003;29:703-8.
15. Cesano G, Livigni S, Vallero A, et al. [Treatment of septic shock with the use of CPFA (associated plasma filtration and adsorption): impact on hemodynamics monitored with PiCCO. G Ital Nefrol 2003;20:258-63.
16. Mariano F, Tetta C, Stella M, et al. Regional citrate anticoagulation in critically ill patients treated with plasma filtration and adsorption. Blood Purif 2004;22:313-9.
17. Page M, Hayi-Slayman D, Ber CE, et al. [Use of coupled plasma filtration adsorption for septic shock treatment]. Ann Fr Anesth Reanim 2007;26:990-3.
18. Turani F, Lanini G, Alessandrini C, et al. Improvement of haemodynamic and respiratory parameters during coupled plasma filtration and adsorption correlates with the clearance of inflammatory mediators. Critical Care 2009;13:284.
19. Formica M, Olivieri C, Livigni S et al. Hemodynamic response to coupled plasmafiltration adsorption in human septic shock. Intensive Care Med 2003;29:703-8.